Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer
Status:
Completed
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
This is a multicenter phase 2 study designed to evaluate the safety and efficacy of eribulin
mesylate in combination with trastuzumab as first line treatment in female subjects with
locally recurrent or metastatic human epidermal growth factor receptor (HER2) positive breast
cancer.